Feline Infectious Peritonitis (FIP) in Cats — Management Guide

Comprehensive, practical guide to diagnosing and managing FIP in cats, including wet vs dry forms, mutation theory, GS‑441524 protocols, monitoring, and prognosis.

Quick Overview

• What it is: Feline infectious peritonitis (FIP) is a progressive, immune‑mediated disease caused when a common feline coronavirus (FCoV) mutates within an individual cat, giving rise to a virus that replicates in macrophages and triggers a damaging inflammatory response.
• Who's at risk: Kittens and young cats (most cases <2 years), cats in multicat environments (shelters, catteries), pedigree breeds (e.g., Bengals, Abyssinians, Birmans), and cats under stress or with immunosuppression are at higher risk.
• Prognosis: Historically nearly uniformly fatal. Since the introduction of antiviral therapy (GS‑441524 and related regimens) many cats can be successfully treated; reported remission/cure rates vary by disease form and protocol but are substantially improved compared with historic outcomes.

Pathophysiology (Explained Simply)

Feline enteric coronavirus (FECV) is common and usually causes mild intestinal infection or no signs. In some cats, random mutations occur in the viral genome inside an infected cat; the mutated form (colloquially “FIPV”) is able to infect and replicate in macrophages. The infected macrophages spread, producing an excessive, dysregulated immune response — vasculitis and granulomatous inflammation — that underlies the clinical signs.

Two clinical patterns occur:

• Effusive or “wet” FIP: prominent protein‑rich fluid accumulates in body cavities (abdomen, chest) due to vasculitis.
• Non‑effusive or “dry” FIP: granulomatous inflammation in organs (liver, kidneys, eyes, brain) causes variable signs without large effusions.

Breed‑specific Risk Factors and Prevalence

• Higher risk: Purebred and pedigree cats — Bengals, Abyssinians, Birmans, Ragdolls, and others have been overrepresented in some studies.
• Environment: Multi‑cat households, shelters, catteries increase exposure and viral load, raising mutation probability.
• Age: Most affected cats are young (median <1–2 years), though any age can be affected.
• Prevalence: FCoV infection is common (seroprevalence varies 20–90% by population); FIP develops in a minority (estimates ~1–5% of FCoV‑infected cats, higher in high‑risk settings).

Clinical Signs and Stages

Signs depend on form and organs affected.

Wet (effusive) FIP

• Abdominal distension/ascites, breathing difficulty (pleural effusion)
• Fever, anorexia, weight loss, lethargy
• Rapid deterioration in many cases

• Chronic fever, weight loss, poor appetite
• Organ‑specific signs: jaundice (liver), ocular changes (uveitis, fibrin, keratic precipitates), neurological signs (ataxia, seizures, behavioral change)

Grading: There is no universally accepted staging system — clinicians classify as effusive vs non‑effusive and by severity (mild/moderate/severe) and by organ involvement (e.g., neurological).

Diagnostic Approach

No single antemortem test is 100% diagnostic for all cases. Diagnosis combines history, exam, clinicopathologic testing, imaging, fluid analysis, and when possible definitive detection of virus in affected tissue.

• Young cat, multi‑cat exposure, progressive signs, fever, effusion, ocular or neurologic signs.

• CBC: often non‑regenerative anemia, lymphopenia.
• Chemistry: hyperbilirubinemia, elevated liver enzymes variably.
• Serum proteins: hyperglobulinemia common; albumin often low. Albumin:globulin (A:G) ratio is useful: A:G <0.6 is suspicious; A:G <0.4 strongly supports FIP in the right clinical context.
• Acute phase proteins: alpha‑1‑acid glycoprotein (AGP) is often markedly elevated in FIP (>1.5 g/L in many cases).

• Typically straw‑colored, viscous, high protein, low to moderate nucleated cell count.
• Total protein often high (>3.5–7 g/dL), albumin low relative to globulins.
• Rivalta test: inexpensive screening test; a positive result supports FIP but is not definitive.
• FCoV RT‑PCR on effusion: high diagnostic value if positive (shows viral RNA); sensitivity/specificity vary by lab and assay.

• Abdominal ultrasound: detects free fluid, organ enlargement, mesenteric lymphadenopathy.
• Chest radiographs/CT to evaluate pleural effusion or pulmonary involvement.

• Cytology of effusion helps exclude other causes but not definitive.
• Biopsy with histopathology showing pyogranulomatous vasculitis plus demonstration of FCoV antigen in macrophages by IHC is the gold standard for definitive diagnosis.

• Consider internal medicine or oncology specialists when diagnosis is uncertain, when neurologic/ocular disease is present, or where advanced diagnostics (biopsy, IHC) are required.

Treatment Options

Important: Until recently, treatment was largely supportive and palliative. The landscape changed with development and clinical use of antivirals active against FIP.

Medical therapy

• Mechanism: inhibits viral RNA polymerase; direct antiviral activity against FCoV.
• Evidence: Field studies and case series demonstrate rapid clinical improvement (fever resolves in days, appetite returns) and substantial cure/remission rates when given daily courses.
• Typical dosing concepts (general guidance — individual dosing must be decided with your veterinarian):

• Response: many cats show marked improvement within 48–72 hours. Reported cure/remission rates in recent studies and field reports range from approximately 70–90% depending on disease severity, dosing, and treatment duration; neurologic cases historically do less well but outcomes are improved with higher dosing and adequate duration.
• Adverse effects: injection‑site discomfort, local inflammation; occasional mild liver enzyme elevations; overall GS‑441524 has been well tolerated in published reports.

• Remdesivir is a prodrug that is metabolized to GS‑441524. Where GS‑441524 is unavailable, remdesivir has been used under veterinary guidance; protocols differ and are best managed by specialists. Availability and legal/regulatory status vary by region.

• Anti‑inflammatories: short courses of corticosteroids were historically used for symptom control but are immunosuppressive and no longer central where antiviral therapy is used.
• Appetite stimulants, antiemetics, fluid therapy, nutritional support.
• Management of specific organ involvement (e.g., anticonvulsants for seizures, topical/systemic therapy for uveitis).

• Molnupiravir and other antivirals are being discussed and used off‑label in some regions; robust controlled data are limited and safety/efficacy must be considered. Work with a specialist before using experimental protocols.

• Surgery is not a treatment for FIP per se. In select cases, therapeutic drainage of large effusions can relieve breathing discomfort but is not curative. Biopsy for diagnosis may be surgical.

Treatment Protocols and Monitoring Response

Initial evaluation and baseline monitoring

• CBC, chemistry profile (including liver enzymes), A:G ratio, AGP (if available), body weight.
• For neurologic/ocular cases, baseline neurological exam and ophthalmic exam; consider advanced imaging (MRI) if indicated.

• First week: daily home observations — appetite, attitude, fever resolution, activity, vomiting.
• First month: recheck at 1–2 weeks and 4 weeks with physical exam and bloodwork. Many clinicians perform CBC/chemistry every 2–4 weeks during treatment.
• Ongoing: monthly checks thereafter, and more frequently if abnormalities arise.

• Rapid clinical improvement: resolution of fever and return of appetite within 48–72 hours is common.
• Weight gain, disappearance of effusion on ultrasound, normalization of A:G ratio and decrease in AGP and globulins over weeks to months.
• For neurologic cases, improvement can be slower; careful neurologic monitoring is needed.

• Relapse can occur, sometimes related to insufficient dosing or duration. Relapses are often managed by resuming antiviral therapy and increasing dose/duration under specialist guidance.

Prognosis and Quality of Life

• Prognosis has shifted from uniformly poor to guarded/hopeful with modern antivirals. Many cats treated early and appropriately with GS‑441524 or equivalent regimens experience complete remission.
• Success rates vary: reported remission/cure in multiple case series often falls in the 70–90% range; neurologic and ocular cases historically had lower success but improved outcomes are reported with higher dosing and longer treatment.
• Quality of life: Cats that respond typically regain appetite, energy, and weight and can return to a good quality of life. Ongoing monitoring and long‑term follow‑up are important.

Living With FIP: Practical Daily Tips

• Administer medication exactly as prescribed (time and route). SC injections require technique and monitoring for injection‑site reactions.
• Keep a daily log: temperature (if taught), appetite, water intake, stool, urine, activity, and any adverse signs.
• Nutrition: high‑quality, palatable food and frequent feeding may help recovery.
• Minimize stress: quiet, comfortable environment, predictable routine.
• Hygiene: FCoV spreads fecal‑orally. In multicat households, good litter box hygiene and reducing crowding can lower transmission risk among cats (though the disease results from mutation within an individual).
• Vaccination and routine preventive care should continue as recommended by your veterinarian once the cat is stable.

When to See Your Vet Urgently

Seek immediate veterinary care if any of the following occur:

• Sudden labored breathing, open‑mouth breathing, severe abdominal distension
• Seizures, collapse, severe ataxia, disorientation
• Persistent vomiting, severe diarrhea, or inability to eat/drink
• Rapid decline in energy, severe jaundice, or any worrying new neurologic signs

Key Takeaways & Practical Considerations

• FIP is caused by a mutated form of feline coronavirus and presents as effusive (wet) or non‑effusive (dry) disease; neurologic and ocular forms require special attention.
• Diagnosis requires a combination of clinical findings, bloodwork (A:G ratio, AGP), effusion analysis, and where possible, confirmation by PCR or IHC on tissue.
• GS‑441524 has transformed FIP management: daily antiviral therapy for at least 12 weeks can produce remission in many cats; dosing must be individualized, especially for neurologic disease.
• Monitoring and follow‑up are essential. Work closely with your veterinarian or a veterinary internal medicine specialist.

References and Further Reading

• Cornell Feline Health Center: Feline Infectious Peritonitis — diagnostic and treatment overview.
• Pedersen NC, et al. (studies on GS‑441524 in cats) — landmark field studies demonstrating efficacy of GS‑441524 for FIP.
• ACVIM and specialty literature reviews on FIP diagnosis and management.

Frequently Asked Questions